Log in

OTCMKTS:OXBDFOxford BioMedica Stock Price, Forecast & News

$9.90
+0.12 (+1.18 %)
(As of 06/1/2020 04:00 PM ET)
Add
Compare
Today's Range
$9.85
Now: $9.90
$10.20
50-Day Range
$8.41
MA: $9.17
$9.79
52-Week Range
$4.51
Now: $9.90
$10.20
Volume6,650 shs
Average Volume2,116 shs
Market Capitalization$761.21 million
P/E RatioN/A
Dividend YieldN/A
Beta1.09
Oxford BioMedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson's, central nervous system disorders, and ocular conditions in Europe and internationally. The company operates through Platform and Product segments. Its LentiVector platform technology integrates genes into non-dividing cells in the brain and retinal cells in the eye, as well as accommodates multiple therapeutic genes. The company's products under development include OXB-102 that is in Phase I/IIa study preparation for the treatment of Parkinson's disease; OXB-202, which is in a Phase I/IIa trial preparation for the prevention of corneal graft rejection; and OXB-302, a gene-based cancer immunotherapy product that has completed pre-clinical development for use in the treatment of a range of cancers, as well as OXB-201 that has completed Phase I trial for the treatment of wet age-related macular degeneration and diabetic retinopathy. It is also developing gene-based therapies, such as SAR 422459 that is in a Phase II trial for the treatment of Stargardt disease; and SAR 421869, which is in Phase I/II trial for the treatment of Usher syndrome 1B. The company has partnerships with Novartis, Sanofi, GlaxoSmithKline, Bioverativ, Orchard Therapeutics, GC LabCell, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations, Immune Design, and Microsoft. Oxford BioMedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.
Read More
Oxford BioMedica logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.29 out of 5 stars


Industry, Sector and Symbol

Industry Private households
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:OXBDF
Previous SymbolNASDAQ:OXBDF
CUSIPN/A
CIKN/A
Phone44-18-6578-3000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$89.14 million

Profitability

Miscellaneous

Employees432
Market Cap$761.21 million
Next Earnings DateN/A
OptionableNot Optionable

Receive OXBDF News and Ratings via Email

Sign-up to receive the latest news and ratings for OXBDF and its competitors with MarketBeat's FREE daily newsletter.

Oxford BioMedica (OTCMKTS:OXBDF) Frequently Asked Questions

How has Oxford BioMedica's stock been impacted by COVID-19 (Coronavirus)?

Oxford BioMedica's stock was trading at $7.7250 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, OXBDF stock has increased by 28.2% and is now trading at $9.90. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Oxford BioMedica?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oxford BioMedica in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Oxford BioMedica.

What price target have analysts set for OXBDF?

1 brokers have issued 1 year price targets for Oxford BioMedica's stock. Their forecasts range from $14.50 to $14.50. On average, they expect Oxford BioMedica's share price to reach $14.50 in the next year. This suggests a possible upside of 46.5% from the stock's current price. View analysts' price targets for Oxford BioMedica.

Has Oxford BioMedica been receiving favorable news coverage?

News headlines about OXBDF stock have been trending very positive this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Oxford BioMedica earned a daily sentiment score of 3.5 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutOxford BioMedica.

Who are some of Oxford BioMedica's key competitors?

Who are Oxford BioMedica's key executives?

Oxford BioMedica's management team includes the following people:
  • Mr. John Dawson, CEO & Exec. Director (Age 59)
  • Mr. Stuart Paynter, CFO & Director
  • Mr. Timothy William Watts, Exec. Officer (Age 61)
  • Mr. Peter Nolan, Consultant (Age 66)
  • Mr. Nick Page, Chief Operations Officer

What is Oxford BioMedica's stock symbol?

Oxford BioMedica trades on the OTCMKTS under the ticker symbol "OXBDF."

How do I buy shares of Oxford BioMedica?

Shares of OXBDF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Oxford BioMedica's stock price today?

One share of OXBDF stock can currently be purchased for approximately $9.90.

How big of a company is Oxford BioMedica?

Oxford BioMedica has a market capitalization of $761.21 million and generates $89.14 million in revenue each year. Oxford BioMedica employs 432 workers across the globe.

What is Oxford BioMedica's official website?

The official website for Oxford BioMedica is www.oxfordbiomedica.co.uk.

How can I contact Oxford BioMedica?

Oxford BioMedica's mailing address is Windrush Court Transport Way, Oxford X0, OX4 6LT. The company can be reached via phone at 44-18-6578-3000.

This page was last updated on 6/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.